Evidence mapPaperPMID 41526641Full record

ArticleScientific reports2026

Zebra bodies recognition by artificial intelligence (ZEBRA): a computational tool for Fabry nephropathy.

Giorgio Cazzaniga, Maurizio Carbone, Raffaella Barretta, Gabriele Casati, Simona Vatrano, Giovanni Gambaro, Gisella Vischini, Irene Capelli, Renzo Mignani, Gianandrea Pasquinelli and 9 more

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Giorgio CazzanigaPathology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Maurizio CarbonePathology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Raffaella BarrettaPathology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Gabriele CasatiPathology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Simona VatranoPathology Unit, Gravina Hospital Caltagirone ASP, Catania, Italy.
Giovanni GambaroDivision of Nephrology, Azienda Ospedaliera Universitaria Integrata Verona, and Department of Medicine, University of Verona, Verona, Italy.
Gisella VischiniNephrology, Dialysis and Renal Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Irene CapelliNephrology, Dialysis and Renal Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Renzo MignaniDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
Gianandrea PasquinelliDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
Federico PieruzziSchool of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Leonardo CarotiNephrology, Dialysis and Transplantation Unit, Careggi University Hospital, Florence, Italy.
Egrina DervishiNephrology, Dialysis and Transplantation Unit, Careggi University Hospital, Florence, Italy.
Marco AllinoviNephrology, Dialysis and Transplantation Unit, Careggi University Hospital, Florence, Italy.
Luca NovelliInstitute of Histopathology and Molecular Diagnosis, Careggi University Hospital, Florence, Italy.
Antonio PisaniNephrology, University Federico II, Naples, Italy.
Albino EccherDepartment of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, University Hospital of Modena, Modena, Italy.
Fabio PagniPathology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Vincenzo L'ImperioPathology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. vincenzo.limperio@unimib.it.

Funding

European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS DIPLOMAT - PNRR-MR1-2022-12375735
6 · The paper itself

Abstract

Fabry disease (FD) is a rare lysosomal storage disorder caused by mutations in the GLA gene, resulting in globotriaosylceramide accumulation. Kidney involvement (Fabry nephropathy) significantly contributes to morbidity and mortality. Diagnosis can be difficult, especially in females or late-onset variants. Renal biopsy remains essential, but interpretation requires expert pathologists. Digital pathology and artificial intelligence (AI) offer promising solutions to support diagnosis. The study analyzed Whole-slide images from renal biopsies of Fabry nephropathy patients to develop and validate a "foamy podocytes" screening AI tool. Two computational tasks were performed: glomerular-level classification, and podocyte-level segmentation. Performance was evaluated using standard metrics. A novel ZEBRA score (fpA/tgA%) was developed to quantify disease burden, and correlations with histological scores and clinical parameters were assessed. EfficientNetB2 achieved the highest classification accuracy (79%) in identifying foamy podocytes. SegFormerB4 had the best segmentation performance (Dice = 0.46, IoU = 0.37). The ZEBRA score effectively distinguished Fabry nephropathy from controls (p < 0.001) and showed good correlation with manual scoring (rs = 0.66-0.71). The AI-assisted ZEBRA pipeline highlights high-risk Fabry nephropathy features to support nephropathologists as a screening tool.

Indexed as

Artificial IntelligenceFabry DiseaseBiopsyClassification AlgorithmsFemaleHumansKidney DiseasesLamellar BodiesMalePathologyPodocytesArtificial intelligenceComputational pathologyDigital pathologyFabry nephropathyRenal biopsy

Identifiers

PMID41526641
PMCPMC12876834

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.